Roche Holding Ltd. (ROG) Given a CHF 231 Price Target by Baader Bank Analysts
A number of other equities research analysts also recently weighed in on ROG. Barclays PLC set a CHF 320 price target on shares of Roche Holding and gave the company a buy rating in a report on Saturday, May 20th. Goldman Sachs Group, Inc. (The) set a CHF 335 price target on shares of Roche Holding and gave the company a buy rating in a report on Saturday, May 20th. J P Morgan Chase & Co reissued a buy rating on shares of Roche Holding in a report on Saturday, May 20th. Jefferies Group LLC set a CHF 305 price target on shares of Roche Holding and gave the company a buy rating in a report on Saturday, May 20th. Finally, Morgan Stanley set a CHF 290 price target on shares of Roche Holding and gave the company a buy rating in a report on Saturday, May 20th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. Roche Holding currently has an average rating of Hold and a consensus price target of CHF 267.53.
Roche Holding (VTX ROG) opened at 243.20 on Tuesday. The firm has a market cap of CHK 207.51 billion and a PE ratio of 21.59. Roche Holding has a 12 month low of CHK 218.30 and a 12 month high of CHK 273.00. The firm’s 50-day moving average is CHK 243.57 and its 200-day moving average is CHK 252.42.
TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/15/roche-holding-ltd-rog-given-a-chf-231-price-target-by-baader-bank-analysts.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.